Skip to main content
Erschienen in: Endocrine 3/2018

21.06.2018 | Original Article

The posterior pharyngeal wall thickness is associated with OSAHS in patients with acromegaly and correlates with IGF-1 levels

verfasst von: Xiaopeng Guo, Yumo Zhao, Man Wang, Lu Gao, Zihao Wang, Zhuhua Zhang, Bing Xing

Erschienen in: Endocrine | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the incidence of obstructive sleep apnea-hypopnea syndrome (OSAHS), explore the structural changes in pharyngeal soft tissue underlying OSAHS development and analyze the correlation between hormone levels and pharyngeal soft tissue changes in patients with untreated acromegaly.

Methods

Twenty-five patients with untreated acromegaly were prospectively enrolled. Pituitary hormones were tested, sellar magnetic resonance imaging was confirmed, overnight polysomnography was conducted, and upper airway computed tomography was performed on these patients.

Results

Patients with untreated acromegaly had a high incidence of OSAHS (52.0%, 13/25). The average age of the patients with OSAHS was 12 years older than that of patients without OSAHS (47.0 ± 8.5 years vs. 35.1 ± 9.5 years, p = 0.003). The posterior pharyngeal soft tissues were thicker in four different planes, including the planes of the soft palate, uvula, tongue and epiglottis (p = 0.003, 0.008, 0.027, and 0.003, respectively), and the soft palate (p = 0.024) was more hypertrophic in patients with acromegaly presenting with OSAHS than patients without OSAHS. The posterior pharyngeal wall thickness (cm) positively correlated with the serum insulin-like growth factor 1 (IGF-1) level (ng/ml) in the planes of the soft palate (slope = 0.001, p = 0.006) and epiglottis (slope = 0.002, p = 0.039).

Conclusions

OSAHS is a common complication in patients with untreated acromegaly, and advanced age is a risk factor. Posterior pharyngeal soft tissue thickening and soft palate hypertrophy are structural changes underlying OSAHS development in patients with acromegaly. Higher IGF-1 levels predict an increase in the posterior pharyngeal soft tissue thickness in patients with acromegaly.
Literatur
4.
Zurück zum Zitat L.M. Fatti, M. Scacchi, A.I. Pincelli, E. Lavezzi, F. Cavagnini, Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 4, 259–262 (2001)CrossRefPubMed L.M. Fatti, M. Scacchi, A.I. Pincelli, E. Lavezzi, F. Cavagnini, Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 4, 259–262 (2001)CrossRefPubMed
5.
Zurück zum Zitat R.R. Grunstein, K.Y. Ho, C.E. Sullivan, Sleep apnea in acromegaly. Ann. Intern. Med. 115, 527–532 (1991)CrossRefPubMed R.R. Grunstein, K.Y. Ho, C.E. Sullivan, Sleep apnea in acromegaly. Ann. Intern. Med. 115, 527–532 (1991)CrossRefPubMed
6.
Zurück zum Zitat W. Hochban, K. Ehlenz, R. Conradt, U. Brandenburg, Obstructive sleep apnoea in acromegaly: the role of craniofacial changes. Eur. Respir. J. 14, 196–202 (1999)CrossRefPubMed W. Hochban, K. Ehlenz, R. Conradt, U. Brandenburg, Obstructive sleep apnoea in acromegaly: the role of craniofacial changes. Eur. Respir. J. 14, 196–202 (1999)CrossRefPubMed
8.
Zurück zum Zitat S. Dostalova, K. Sonka, Z. Smahel et al. Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly. Eur. J. Endocrinol. 144, 491–497 (2001)CrossRefPubMed S. Dostalova, K. Sonka, Z. Smahel et al. Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly. Eur. J. Endocrinol. 144, 491–497 (2001)CrossRefPubMed
17.
Zurück zum Zitat M.S. Ip, K.C. Tan, W.C. Peh, K.S. Lam, Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin. Endocrinol. 55, 477–483 (2001)CrossRef M.S. Ip, K.C. Tan, W.C. Peh, K.S. Lam, Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin. Endocrinol. 55, 477–483 (2001)CrossRef
20.
Zurück zum Zitat F. Rosenow, S. Reuter, U. Deuss et al. Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin. Endocrinol. 45, 563–569 (1996)CrossRef F. Rosenow, S. Reuter, U. Deuss et al. Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin. Endocrinol. 45, 563–569 (1996)CrossRef
22.
Zurück zum Zitat C.F. Mello Jr, H.A. Guimaraes Filho, C.A. Gomes, C.C. Paiva, Radiological findings in patients with obstructive sleep apnea. J. Bras. Pneumol. 39, 98–101 (2013)CrossRef C.F. Mello Jr, H.A. Guimaraes Filho, C.A. Gomes, C.C. Paiva, Radiological findings in patients with obstructive sleep apnea. J. Bras. Pneumol. 39, 98–101 (2013)CrossRef
23.
Zurück zum Zitat L. Pelttari, O. Polo, E. Rauhala et al. Nocturnal breathing abnormalities in acromegaly after adenomectomy. Clin. Endocrinol. 43, 175–182 (1995)CrossRef L. Pelttari, O. Polo, E. Rauhala et al. Nocturnal breathing abnormalities in acromegaly after adenomectomy. Clin. Endocrinol. 43, 175–182 (1995)CrossRef
25.
Zurück zum Zitat B.L. Herrmann, T.E. Wessendorf, W. Ajaj et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur. J. Endocrinol. 151, 309–315 (2004)CrossRefPubMed B.L. Herrmann, T.E. Wessendorf, W. Ajaj et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur. J. Endocrinol. 151, 309–315 (2004)CrossRefPubMed
26.
Zurück zum Zitat C. Berg, T.E. Wessendorf, F. Mortsch et al. Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur. J. Endocrinol. 161, 829–835 (2009)CrossRefPubMed C. Berg, T.E. Wessendorf, F. Mortsch et al. Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur. J. Endocrinol. 161, 829–835 (2009)CrossRefPubMed
Metadaten
Titel
The posterior pharyngeal wall thickness is associated with OSAHS in patients with acromegaly and correlates with IGF-1 levels
verfasst von
Xiaopeng Guo
Yumo Zhao
Man Wang
Lu Gao
Zihao Wang
Zhuhua Zhang
Bing Xing
Publikationsdatum
21.06.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1631-3

Weitere Artikel der Ausgabe 3/2018

Endocrine 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.